Wells Fargo & Company Genprex, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.19 - $0.37 $4 - $8	22 Added 5.46%	425 $0
Q3 2023 Nov 13, 2023	BUY	$0.37 - $1.04 $10 - $30	29 Added 7.75%	403 $0
Q2 2023 Aug 15, 2023	BUY	$0.74 - $1.1 $31 - $46	42 Added 12.65%	374 $0
Q1 2023 May 12, 2023	BUY	$0.76 - $1.78 $3 - $8	5 Added 1.53%	332 $0
Q4 2022 Feb 13, 2023	SELL	$1.0 - $58.8 $1,191 - $70,030	-1,191 Reduced 78.46%	327 $0
Q3 2022 Nov 14, 2022	BUY	$1.32 - $58.0 $47 - $2,088	36 Added 2.43%	1,518 $2,000
Q2 2022 Aug 12, 2022	BUY	$1.28 - $2.31 $29 - $53	23 Added 1.58%	1,482 $2,000
Q1 2022 May 16, 2022	SELL	$1.82 - $3.5 $3,818 - $7,343	-2,098 Reduced 58.98%	1,459 $4,000
Q4 2021 Feb 14, 2022	SELL	$1.21 - $2.7 $30,489 - $68,034	-25,198 Reduced 87.63%	3,557 $4,000
Q3 2021 Nov 15, 2021	SELL	$2.59 - $3.36 $49 - $63	-19 Reduced 0.07%	28,755 $77,000
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.87 $26,885 - $42,101	-8,645 Reduced 23.1%	28,774 $96,000
Q1 2021 May 13, 2021	SELL	$3.66 - $7.67 $279,777 - $586,310	-76,442 Reduced 67.14%	37,419 $161,000
Q4 2020 Feb 09, 2021	BUY	$3.03 - $5.51 $297,136 - $540,338	98,065 Added 620.82%	113,861 $472,000
Q3 2020 Nov 05, 2020	SELL	$2.9 - $4.29 $1,284 - $1,900	-443 Reduced 2.73%	15,796 $53,000
Q2 2020 Aug 13, 2020	BUY	$1.99 - $3.64 $32,040 - $58,607	16,101 Added 11667.39%	16,239 $51,000
Q1 2020 May 14, 2020	BUY	$0.28 - $6.23 $38 - $859	138 New	138 $0

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.